In the predicted target gene interrogation interface of the miR-326 3p-arm, SMTNL2 was found to have approximately 20-fold downregulation and satisfactory scores for miRDB and targetScan, which are known to be downregulated in kidney cancer (26). Here, SMTNL2 is linked to kidney cancer.